Cargando…

Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study

BACKGROUND: In the prepertuzumab era, we evaluated the clinical outcomes of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who underwent first-line trastuzumab-based or lapatinib-based therapy according to prior exposure to (neo)adjuvant trastuzumab....

Descripción completa

Detalles Bibliográficos
Autores principales:	Blondeaux, Eva, Ferreira, Arlindo R, Poggio, Francesca, Puglisi, Fabio, Bighin, Claudia, Sottotetti, Federico, Montemurro, Filippo, Poletto, Elena, Lai, Antonella, Sini, Valentina, Minuti, Gabriele, Mura, Silvia, Fontana, Andrea, Fregatti, Piero, Cardinali, Barbara, Lambertini, Matteo, Del Mastro, Lucia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437709/ https://www.ncbi.nlm.nih.gov/pubmed/32817059 http://dx.doi.org/10.1136/esmoopen-2020-000719

Ejemplares similares

The PREgnancy and FERtility (PREFER) Study Investigating the Need for Ovarian Function and/or Fertility Preservation Strategies in Premenopausal Women With Early Breast Cancer
por: Blondeaux, Eva, et al.
Publicado: (2021)

Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
por: Yuan, Ye, et al.
Publicado: (2022)

Management of young women with early breast cancer
por: Poggio, Francesca, et al.
Publicado: (2018)

Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study
por: Blondeaux, Eva, et al.
Publicado: (2020)

Successful Trastuzumab-Deruxtecan Rechallenge After Interstitial Lung Disease: A Case Report
por: de Weger, Vincent A., et al.
Publicado: (2023)

Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study
por: Sanglier, Thibaut, et al.
Publicado: (2023)

Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population
por: Yang, Fan, et al.
Publicado: (2020)

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib
por: Wang, Leiping, et al.
Publicado: (2011)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
por: Cheong, E. Von, et al.
Publicado: (2021)

Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study
por: Li, Feng, et al.
Publicado: (2021)

Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review
por: Poggio, Francesca, et al.
Publicado: (2019)

A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment
por: Lim, Bora, et al.
Publicado: (2019)

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
por: Bianchini, Giampaolo, et al.
Publicado: (2017)

Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer
por: Parisi, Francesca, et al.
Publicado: (2020)

T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study
por: Schettini, F., et al.
Publicado: (2021)

Dramatic Response to Trastuzumab Deruxtecan Rechallenge in a Patient with HER2-Positive Gastric Cancer: A Case Report
por: Ogata, Takatsugu, et al.
Publicado: (2022)

A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
por: Patel, Tejal A., et al.
Publicado: (2019)

Resistance to Trastuzumab
por: Vivekanandhan, Sneha, et al.
Publicado: (2022)

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial
por: Alba, E, et al.
Publicado: (2014)

Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells
por: OKITA, RIKI, et al.
Publicado: (2015)

Trastuzumab-resistant breast cancer cells-derived tumor xenograft models exhibit distinct sensitivity to lapatinib treatment in vivo
por: Liu, Hao, et al.
Publicado: (2023)

The PREgnancy and FERtility (PREFER) study: an Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patients
por: Lambertini, Matteo, et al.
Publicado: (2017)

Trastuzumab-induced thrombocytopenia after eight cycles of trastuzumab treatment
por: Zhou, Qiong, et al.
Publicado: (2020)

Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
por: Sim, Sung Hoon, et al.
Publicado: (2019)

Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort
por: Moinard-Butot, Fabien, et al.
Publicado: (2022)

Update on the Management of Breast Cancer during Pregnancy
por: Poggio, Francesca, et al.
Publicado: (2020)

Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis
por: Guérin, Annie, et al.
Publicado: (2014)

Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report
por: Jiao, Xiao-Dong, et al.
Publicado: (2018)

Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
por: Waller, Cornelius F., et al.
Publicado: (2021)

Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study
por: Gori, Stefania, et al.
Publicado: (2016)

Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel
por: Bianchini, Giampaolo, et al.
Publicado: (2022)

Immune Effects of Trastuzumab
por: Nuti, Marianna, et al.
Publicado: (2011)

Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study
por: Xu, Binghe, et al.
Publicado: (2016)

Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006–2014)
por: Daniels, Benjamin, et al.
Publicado: (2018)

Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit
por: Triulzi, Tiziana, et al.
Publicado: (2018)

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivation
por: Wang, Yen-Chao, et al.
Publicado: (2011)

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial
por: Witzel, I, et al.
Publicado: (2012)

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer
por: Moreno-Aspitia, Alvaro, et al.
Publicado: (2013)

Dual HER2 Suppression with Lapatinib plus Trastuzumab for Metastatic Inflammatory Breast Cancer: A Case Report of Prolonged Stable Disease
por: Ogawa, Lauren, et al.
Publicado: (2018)

Dual-targeting strategy using trastuzumab and lapatinib in a patient with HER2 gene amplification in recurrent metachronous metastatic gallbladder carcinoma
por: Ye, Minfeng, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ca5q9qhgsvdsu8s175vdtuhev7